News

Multivariate dimensional association scores resulted in an overall increase and normalization with age in the ADHD.

While investigators acknowledged the need for more high-quality, large-scale trials, cognitive behavioral therapy (CBT) serves as a promising intervention for insomnia in patients with cancer.

A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.

Regardless of frailty status, edoxaban 15 mg was associated with significantly reduced incidence of the study outcomes compared with placebo.

IBS-type symptoms were not linked to an increased likelihood of the need for glucocorticosteroids or flare, escalation, hospitalization, or intestinal resection.

Pharmacovigilance studies sifting through FDA adverse event reports confirm ocular side effects from PCSK9 inhibitors are infrequent and minor.

In this episode of Diabetes Dialogue, which was filmed just days after the conclusion of ADCES 22, our hosts take the time to dive deeper into the conference, their favorite sessions, and how the ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

The investigational treatment SYNB1353 received FDA Fast Track Designation for homocystinuria (HCU), a rare metabolic disorder.

Vaccine-associated myocarditis was largely restricted to men younger than 40 years, according to the new findings.

Real time CGM was significantly greater time in range, lower time below range, and lower glycemic variability compared to intermittently scanned CGM.

The investigational therapy is being evaluated in a phase 2 study for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD on hemodialysis.

The meta-analysis showed an increased odds ratio of developing postpartum depression when the maternal family had a history of psychiatric disorders.

Patients over 21 years who developed acne presented with different clinical characteristics than younger patients.

Announced on Aug. 22, the US FDA's clearance of the Omnipod 5 AID system in type 1 diabetes for patients aged 2 years and older comes less than 7 months after receiving clearance in patients aged 6 years and older.

Data suggest eyes with a higher ratio of drops taken versus prescribed were significantly more likely to achieve target IOP at 6 months or 1 year.

Endoscopic subscores can determine whether a patient is a suitable candidate for dose reduction.

Dextromethorphan HBr-bupropion HCI (Auvelity) is developed by Axsome Therapeutics.

No advantage was associated with blue light-filtering IOLs in terms of risk of all-cause or traffic-related injury and comfort with driving.

Data suggest most patients who receive a new diagnosis of PACG in the United States do not have a prior diagnosis of anatomical narrow angle.

In this article, readers will find a collection of the on-site coverage of the Association of Diabetes Care and Education Specialist (ADCES) 2022 annual meeting from Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives.

Occult HBV infection prevalence in blood donors was 0.06% in low-endemicity countries, 0.12% in intermediate-endemicity countries, and 0.98% in high-endemicity countries.

The scientific statement reviews symptoms associated with ACS, heart failure, valvular disorders, stroke, rhythm disorders, and peripheral vascular disease.

Some noticeable presenting features included jaundice, vomiting, and diarrhea.

Significant rapid improvement were observed in both signs and symptoms of thyroid eye disease at week 6 after 2 infusions of 10mg/kg VRDN-001.

Ultra-widefield fluorescein angiography allow more accurate risk identification of eyes with non proliferative diabetic retinopathy than baseline severity level alone in new findings.

A systematic literature review identifies 41 unique definitions for psoriasis remission among 106 studies.

An increasing retinal nonperfusion index was associated with a significantly higher risk of Diabetic Retinopathy Severity Scale worsening.

The FDA approved esketamine in 2019 for major depressive disorder.